A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
Clinical trial NCT05604898 · UNKNOWN
Trial details
- NCT number
- NCT05604898
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-01
- Primary completion
- 2023-05-01
- Enrollment
- 139
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.